LAB

The past six months (April to October 2026) saw several significant events for Standard BioTools, Inc. (LAB) stock. In April 2026, the company announced new product innovations in plasma and single-cell proteomics, including the SomaScan Select 3.7K Assay, Single SOMAmer Reagents, and the next-generation CyTOF XT PRO system. August 2026 brought the second-quarter financial results, reporting $20.1 million in revenue and an 84% year-over-year improvement in adjusted EBITDA, alongside news that its merger with Treeline Biosciences was progressing towards a stockholder vote and expected to close by year-end. In September 2026, multiple investor alerts and legal inquiries from M&A class action firms emerged concerning potential mergers involving LAB. On September 30, 2026, Standard BioTools provided an update on the sale of its Mass Cytometry business. On October 5, 2026, the company announced a definitive agreement to sell its Microfluidics business to ARCHIMED, with the transaction anticipated to close in approximately 30 days. Finally, on October 9, 2026, Standard BioTools filed an amended S-4/A registration statement for the issuance of up to 364,223,328 common shares in its proposed all-stock merger with Treeline Biosciences, detailing the agreements to sell the microfluidics business to ARCHIMED and the mass cytometry business to Element Biosystems, LLC. The merger with Treeline Biosciences requires stockholder approval and is expected to result in former Treeline holders owning approximately 84% of the combined company. As of September 28, 2026, the stock price was $0.73 per share, a 42.73% decline from $1.27 per share on September 29, 2025, trading near the lower end of its 52-week range of $0.64 to $1.68 as of September 18, 2026.